Alerts

Linagliptin has received approval in Europe for the treatment of type 2 diabetes. Abbott is permanently discontinuing the FreeStyle Navigator CGMS System in the U.S. Supplies will continue to be available until March 2012. EpiPen and EpiPen Jr single packages have been discontinued and will be supplied in 2-Paks only. …

Bayer is recalling Contour® and Contour® TS test strips in the US According to Bayer this recall applies to 10 and 25 count test strip vials for the Contour® and 10 count test strip vials for the Contour® TS. The company also noted the recall applies to US retail stocks, …

Tylenol Maker Lowers Maximum Dose McNeil Consumer Healthcare announced it is lowering the maximum daily dose instructions for Extra Strength Tylenol to six pills a day (3,000 mg) to reduce the risk of acetaminophen overdose and possible kidney problems.

Bydureon Coming Soon See this week’s Item #1, Lilly Resubmits Bydureon to FDA, for more information.

Dapagliflozin rejected by FDA, but AstraZeneca’s new antiplatelet agent, Brilinta (ticagrelor), is approved.

Artificial Pancreas Closer to Reality See this week’s Item #1, ADA: Scientists Getting Closer to Artificial Pancreas.

BYDUREON™ Receives Marketing Authorization in Europe BYDUREON showed statistically significant improvements in glycemic control based on reduction of A1C (a measure of average blood sugar over three months) between 1.5 and 1.9 percent after six months.

FDA Reminder Warning on Liraglutide FDA warns healthcare professionals to closely monitor patients with diabetes receiving liraglutide injections. For more information, follow this link.

  Germany & France suspend the use of Actos, a TZD diabetes drug, due to worries about a possible link to bladder cancer. Interim results from trials in the U.S. one of which began in 2003 and is slated to last 10 years, have so far not confirmed a clear …

Sanofi touts promising Ph3 results for its diabetes GLP-1 drug: once-daily lixisenatide See this week’s Item #6, Sanofi’s Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study.